What Medical Mondays is, how companies are considered, and what investors look for — a reference for founders preparing to pitch.
What Medical Mondays is
Medical Mondays is a virtual healthcare investor syndicate bringing together 80+ healthcare-focused angel groups, venture funds, hospital partners, and incubators across the country to evaluate early-stage healthcare, medtech, diagnostics, digital health, and therapeutics startups together. Member groups fund both pediatric and adult healthcare innovations. It runs every Monday, 8:00–10:00 am PT. Each session features three vetted startups nominated by member groups. The format per company is a 10-minute pitch, 10-minute investor Q&A, and a 10-minute internal investor-only debrief. There is no cost to present or to participate.
How companies are considered
Companies are nominated by member groups or referral partners and onboarded (at no cost) through the coordinating SBDC (Small Business Development Center in Orange County CA or Austin TX). Onboarding is a short intake plus an SBDC sign-up; companies do not need to be located in Texas or California, though a brief out-of-area acknowledgment is requested if onboarding through the Austin SBDC without a local address. A pre-pitch readiness review is done before a company is scheduled.
Deal-structure requirements
These are structural and category-agnostic — they apply regardless of how strong the science or team is:
Equity rounds: preferred stock only. Common-stock rounds are not considered.
No pre-money SAFEs and no uncapped notes/SAFEs. Post-money SAFEs are acceptable but not preferred.
Preferred structures: priced equity rounds and capped convertible notes.
Only US companies can apply.
A lead / main investor is strongly preferred, and expected for rounds above ~$3M. On SAFEs and convertible notes there is no formal "lead" — here it means the group that set or accepted the terms by investing (usually after doing due diligence).
Round progress: on larger rounds (~$3–7M), roughly 20% of the round should already be committed; smaller rounds should generally have some capital closed and at least one group that has performed due diligence. Companies with nothing closed may be considered as an exception.
Closing date must be at least 60 days after the Medical Mondays pitch date.
Must be a C-Corporation.
Deal terms must be disclosed up front — include the current round terms (amount, instrument, and valuation/cap) in the deck.
Stage readiness by category
Devices & diagnostics (implantable / surgical / monitoring / imaging / lab): prototype completed, at or near design freeze, with data demonstrating the solution is viable.
Digital health: at minimum customer pilots; ideally paying customers.
Biotech / therapeutics: past the pre-clinical stage, with a credible path to the clinic. New drug compounds are not considered — only repurposed drugs pursuing a 505(b)(2) pathway, or a novel method of delivering a drug, qualify. (A new drug may be considered only as an exception: a very strong investor champion and existing human data.)
Tools / infrastructure: beyond prototype, similar bar to digital health.
What investors look for in the pitch
A strong Medical Mondays pitch is clear, honest, and anticipates the hard questions. Investors scan quickly for:
A clear one-liner — what you do, for whom, and why now, in plain language.
Pain and urgency — a real problem with sharp stakes and a believable "this hurts today" narrative.
The customer — who buys first, who uses it, and who holds the budget and authority; evidence you understand their current workflow and why it's realistic for them to switch from what they use today to your solution.
Solution clarity and differentiation — what you built and why you win versus incumbents, in-house builds, and emerging startups using new technology. Honest competitive landscape, not just today's named competitors.
Business model — your price, who pays, and your gross margin: pricing that makes sense for the customer and margins that work for the company.
Adoption and how the purchase is paid for — how the product gets adopted in real settings; for clinical products, the value-analysis-committee/payer view, whether your product is absorbed inside the DRG/bundled payment (so the savings must cover your price) and/or brings your customer additional revenue through a separate payment, whether that relies on an existing code or a new one you will need to obtain, and the payback for the buyer.
Why the product matters at all — for diagnostics especially, why diagnosing changes management when treatment may be cheap or empirical.
Moat / defensibility — IP and why you get stronger over time (data, distribution, workflow lock-in, network).
Traction — any evidence of pull: revenue, usage, retention, LOIs, pilots, quality of waitlist.
Market size with a wedge — a focused, credible beachhead and an expansion path, not only a giant TAM.
Go-to-market — the first channel that works, the sales motion, and why you can reach buyers.
Financial projections — for companies whose exit depends on revenue (rather than on an FDA approval or a data readout), a simple P&L is preferable to charts that show revenue alone: revenue and expenses broken down into cost of goods, R&D, regulatory, sales and marketing, and G&A, with the assumptions behind them (units sold, or number of clients or contracts per year). Take it out to your planned exit year.
Exit trigger: a clinical data readout, regulatory approval, or a revenue level. Investors expect it to match how companies like yours are actually acquired:
Therapeutics — some are acquired at preclinical or Phase I, while others are not bought until Phase II or later; it depends on the therapeutic area, the asset and the strength of the data. Don't assume an early exit — investors will expect comparable deals in your space that support the stage you're claiming.
Diagnostics — acquirers look for proven clinical utility, a reimbursement path that is working or clearly in sight, and growing test volume; clearance or validation data alone is usually not enough.
Devices on a PMA path — for the most part, expected to exit once the clinical data is out, just before formal FDA approval.
Devices on a 510(k) or De Novo path — rarely bought on FDA clearance alone, before commercial traction.
Rounds to exit: how many more rounds, and how large.
Comparable exits and exit size: recent acquisitions of companies like yours at the same stage as your trigger, and what they sold for. Your projected exit value should be in line with those deals — an exit on early data is usually much smaller than one on commercial revenue.
Likely acquirers: who would buy you (see roadmap to exit graphic below).
A clear ask — how much, cap or valuation, what milestones it buys, runway, and what success looks like. Many investors look for roughly a 10x return on an exit about five years out, so a cap or valuation that leaves room for that at a realistic exit for your category makes the round easier to fill. It isn't a hard rule — some investors in the room invest below 10x, and a shorter path to exit can work with a lower multiple.
Roadmap to exit
Medical Mondays prioritizes companies with a reasonable chance to exit in five years or less. We want to see the entire roadmap to exit on a single slide — the sequence of rounds, the capital raised at each, the milestone that unlocks the next step, and the exit trigger, timing, and likely acquirers at the end.
Use the format below as a reference for the slide we want to see:
Think of this as your subway map to exit: the final station is your exit, and each funding round is a stop along the way you pass through to reach it. Every station shows the year, round, amount raised, and the key milestone that gets you to the next stop.
Be ready to answer (a quick self-check before pitching)
Companies that do well can answer these crisply:
Who is your single closest competitor — including any emerging startup — and exactly why does a customer choose you over them?
Who actually uses and pays for this, and what behavior has to change for adoption? Is your product absorbed inside the DRG/bundled payment, and/or does it bring your customer additional revenue — and does that rely on an existing code or a new one?
For devices/diagnostics: what evidence do you have that the product works (bench, cadaver, animal or clinical)?
For diagnostics: why does diagnosing change patient management here?
For therapeutics: what is the endpoint, is the proof-of-principle real for that endpoint, and what is the time and path to the clinic?
What is your round structure (preferred? capped? US entity? lead / main investor committed?), and what are the unit economics for the buyer and for you?
What triggers your exit (a data readout, regulatory approval, or revenue), who buys you, and what does the path of rounds to get there look like?